Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

Related Articles by Review for PubMed (Select 20082117)

1.

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS.

Invest New Drugs. 2011 Jun;29(3):489-98. doi: 10.1007/s10637-009-9376-8. Epub 2010 Jan 16.

PMID:
20082117
2.

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

Graziani G, Tentori L, Navarra P.

Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21930211
3.

Ipilimumab: in previously treated patients with advanced melanoma.

Sanford M.

BioDrugs. 2012 Jun 1;26(3):185-93. doi: 10.2165/11208200-000000000-00000. Review.

PMID:
22530681
4.

How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.

Wolchok J.

Ann Oncol. 2012 Sep;23 Suppl 8:viii15-21. doi: 10.1093/annonc/mds258. Review.

5.

Ipilimumab: showing survival benefit in metastatic melanoma.

Minchom A, Young K, Larkin J.

Future Oncol. 2011 Nov;7(11):1255-64. doi: 10.2217/fon.11.105. Review.

PMID:
22044200
6.

Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.

Boasberg P, Hamid O, O'Day S.

Semin Oncol. 2010 Oct;37(5):440-9. doi: 10.1053/j.seminoncol.2010.09.004. Review.

PMID:
21074058
8.

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

Weber J.

Oncologist. 2008;13 Suppl 4:16-25. doi: 10.1634/theoncologist.13-S4-16. Review.

9.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R.

Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Review.

PMID:
21074069
10.
11.

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.

Simeone E, Ascierto PA.

J Immunotoxicol. 2012 Jul-Sep;9(3):241-7. doi: 10.3109/1547691X.2012.678021. Epub 2012 Apr 23. Review.

PMID:
22524673
12.

Upcoming strategies for the treatment of metastatic melanoma.

Spagnolo F, Queirolo P.

Arch Dermatol Res. 2012 Apr;304(3):177-84. doi: 10.1007/s00403-012-1223-7. Epub 2012 Feb 17. Review.

PMID:
22350184
13.

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.

Lipson EJ, Drake CG.

Clin Cancer Res. 2011 Nov 15;17(22):6958-62. doi: 10.1158/1078-0432.CCR-11-1595. Epub 2011 Sep 7. Review.

14.

Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.

Lens M, Ferrucci PF, Testori A.

Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):105-13. Review.

PMID:
18537753
15.

Ipilimumab for advanced melanoma: a pharmacologic perspective.

Trinh VA, Hagen B.

J Oncol Pharm Pract. 2013 Sep;19(3):195-201. doi: 10.1177/1078155212459100. Epub 2012 Oct 9. Review.

16.

The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F.

Eur J Cancer. 2012 Jan;48(2):237-42. doi: 10.1016/j.ejca.2011.09.018. Epub 2011 Oct 24. Review.

PMID:
22030452
17.

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.

Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ.

Ann N Y Acad Sci. 2013 Jul;1291:1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17. Review.

18.

New drugs in melanoma: it's a whole new world.

Eggermont AM, Robert C.

Eur J Cancer. 2011 Sep;47(14):2150-7. doi: 10.1016/j.ejca.2011.06.052. Epub 2011 Jul 27. Review.

PMID:
21802280
19.

Ipilimumab in the treatment of melanoma.

Trinh VA, Hwu WJ.

Expert Opin Biol Ther. 2012 Jun;12(6):773-82. doi: 10.1517/14712598.2012.675325. Epub 2012 Apr 14. Review.

PMID:
22500861
20.

Profile of ipilimumab and its role in the treatment of metastatic melanoma.

Patel SP, Woodman SE.

Drug Des Devel Ther. 2011;5:489-95. doi: 10.2147/DDDT.S10945. Epub 2011 Dec 16. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk